Publicado

2025-03-17

Medication-related osteonecrosis of the jaw (MRONJ)

Osteonecrosis de la mandíbula relacionada con medicamentos (ONMRM)

Osteonecrose da mandíbula relacionada a medicamentos (ONMRM)

DOI:

https://doi.org/10.15446/rcciquifa.v53n3.119215

Palabras clave:

Bisphosphonate–associated osteonecrosis of the jaw, osteonecrosis, maxilla, mandible, drug effects, pharmaceutical preparation (en)
Osteonecrosis de la mandíbula asociada a los bifosfonatos, osteonecrosis, maxilar, mandíbula, efectos de medicamentos, preparación farmacéutica (es)
Osteonecrose da mandíbula associada a bifosfonatos, osteonecrose, maxilar, mandíbula, efeitos de medicamentos, preparação farmacêutica (pt)

Descargas

Autores/as

  • Katherine Cuenca-León Universidad Católica de Cuenca, Cuenca 010105, Ecuador
  • Darlin Riofrio Ministry of Health, Dentistry Department, Cuenca 010105, Ecuador
  • Santiago Reinoso-Quezada Universidad Católica de Cuenca, Cuenca 010105, Ecuador
  • Anabel Solano-Jara Universidad Católica de Cuenca, Cuenca 010105, Ecuador
  • Jaime Cuenca-León Universidad de Cuenca, Cuenca 010107, Ecuador
  • Edisson-Mauricio Pacheco-Quito Universidad Católica de Cuenca, Cuenca 010105, Ecuador

Introduction: Medication-related osteonecrosis of the jaw, formerly known as bisphosphonate-associated osteonecrosis of the jaw, is a syndrome first described in 2003. Prescription drugs such as bisphosphonates, denosumab and anti-angiogenic agents, including monoclonal antibodies, have been implicated in the development of medication-related osteonecrosis of the jaw (MRONJ). Purpose: The aim of this research was to investigate drugs related to osteonecrosis of the jaw. Method: This were a quantitative, cross-sectional descriptive study, using a search of scientific databases to collect information on the drugs associated with the development of drug-related osteonecrosis of the jaw. Result: Bisphosphonates have been associated with the development of osteonecrosis of the jaw, as they inhibit osteoclastic activity by altering bone remodeling. Denosumab was introduced as a more effective alternative to bisphosphonates; however, it has also been linked to the production of osteonecrosis of the jaw, as this drug induces a sustained decrease in bone turnover. Conclusions: Osteonecrosis of the jaw has been linked to some drugs, which include bisphosphonates, especially zoledronic acid. Another drug that has been implicated in osteonecrosis of the jaw is denosumab, which is used for the treatment of osteoporosis and metastatic bone disease.

Introducción: La osteonecrosis de la mandíbula relacionada con la medicación, anteriormente conocida como osteonecrosis de la mandíbula asociada a los bisfosfonatos, es un síndrome descrito por primera vez en 2003. Medicamentos recetados como los bisfosfonatos, denosumab y agentes antiangiogénicos, incluidos los anticuerpos monoclonales, han sido implicados en el desarrollo de la osteonecrosis de la mandíbula relacionada con la medicación (MRONJ, por sus siglas en inglés). Propósito: El objetivo de esta investigación fue investigar los medicamentos relacionados con la osteonecrosis de la mandíbula. Método: Este fue un estudio descriptivo cuantitativo, transversal, utilizando una búsqueda en bases de datos científicas para recopilar información sobre los medicamentos asociados con el desarrollo de la osteonecrosis de la mandíbula relacionada con la medicación. Resultado: Los bisfosfonatos han sido asociados con el desarrollo de osteonecrosis de la mandíbula, ya que inhiben la actividad osteoclástica al alterar la remodelación ósea. El denosumab fue introducido como una alternativa más efectiva a los bisfosfonatos; sin embargo, también ha sido relacionado con la producción de osteonecrosis de la mandíbula, ya que este medicamento induce una disminución sostenida en el recambio óseo. Conclusiones: La osteonecrosis de la mandíbula ha sido relacionada con algunos medicamentos, que incluyen los bisfosfonatos, especialmente el ácido zoledrónico. Otro medicamento que ha sido implicado en la osteonecrosis de la mandíbula es el denosumab, que se utiliza para el tratamiento de la osteoporosis y la enfermedad ósea metastásica.

Introdução: A osteonecrose da mandíbula relacionada a medicamentos, anteriormente conhecida como osteonecrose da mandíbula associada a bifosfonatos, é uma síndrome descrita pela primeira vez em 2003. Medicamentos prescritos como bifosfonatos, denosumabe e agentes antiangiogênicos, incluindo anticorpos monoclonais, têm sido implicados na desenvolvimento de osteonecrose da mandíbula relacionada a medicamentos (MRONJ, na sigla em inglês). Objetivo: O objetivo desta pesquisa foi investigar medicamentos relacionados à osteonecrose da mandíbula. Método: Este foi um estudo quantitativo, transversal e descritivo, utilizando uma busca em bases de dados científicas para coletar informações sobre medicamentos associados ao desenvolvimento de osteonecrose da mandíbula relacionada a medicamentos. Resultado: Os bifosfonatos têm sido associados ao desenvolvimento de osteonecrose da mandíbula, pois inibem a atividade osteoclástica alterando a remodelação óssea. O denosumab foi introduzido como uma alternativa mais eficaz aos bifosfonatos; No entanto, também tem sido relacionado com a produção de osteonecrose da mandíbula, uma vez que este medicamento induz uma diminuição sustentada da remodelação óssea. Conclusões: A osteonecrose da mandíbula tem sido associada a alguns medicamentos, incluindo os bifosfonatos, especialmente o ácido zoledrônico. Outro medicamento implicado na osteonecrose da mandíbula é o denosumabe, usado para tratar a osteoporose e doenças ósseas metastáticas.

Referencias

1. L. Dunphy, G. Salzano, B. Gerber, J. Graystone, Medication-related osteonecrosis (MRONJ) of the mandible and maxilla, BMJ Case Reports, 13(1), e224455 (2020). Doi: https://doi.org/10.1136/bcr-2018-224455

2. M. Diniz-Freitas, J. Fernández-Feijoo, P.D. Dios, X. Pousa, J. Limeres, Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report, Journal of Clinical Periodontology, 45(5), 570-577 (2018). Doi: https://doi.org/10.1111/jcpe.12882

3. A. Matsumoto, M. Sasaki, R. Schmelzeisen, Y. Oyama, Y. Mori, P. Voss, Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab, Clinical Oral Investigations, 21(1), 127-134 (2017). Doi: https://doi.org/10.1007/s00784-016-1762-y

4. J. Sunyecz, R. Derman, Update on the use of bisphosphonates in the management of postmenopausal osteoporosis by obstetricians-gynecologists, Obstetrical & Gynecological Survey, 62(6), 407-416 (2007). Doi: https://doi.org/10.1097/01.ogx.0000266070.47052.52

5. A. Jaiman, D. Sabat, S. Arora, M.A. Hafez, We need a break: Bisphosphonates, Journal of Clinical Orthopaedics and Trauma, 4(1), 11-14 (2013). Doi: https://doi.org/10.1016/j.jcot.2013.01.010

6. L. Chen, G. Wang, F. Zheng, H. Zhao, H. Li, Efficacy of bisphosphonates against osteoporosis in adult men: A meta-analysis of randomized controlled trials, Osteoporosis International, 26(9), 2355-2363 (2015). Doi: https://doi.org/10.1007/s00198-015-3148-4

7. M. Drake, B. Clarke, S. Khosla, Bisphosphonates: Mechanism of action and role in clinical practice, Mayo Clinic Proceedings, 83(9), 1032-1045 (2008). Doi: https://doi.org/10.4065/83.9.1032

8. A. Kuźnik, A. Październiok-Holewa, P. Jewula, N. Kuźnik, Bisphosphonatesmuch more than only drugs for bone diseases, European Journal of Pharmacology, 866, 172773 (2020). Doi: https://doi.org/10.1016/j.ejphar.2019.172773

9. J. Klara, J. Lewandowska-Łańcucka, How efficient are alendronate-nano/biomaterial combinations for anti-osteoporosis therapy? An evidence-based review of the literature, International Journal of Nanomedicine, 17, 6065-6094 (2022). Doi: https://doi.org/10.2147/IJN.S388430

10. S.A. Lozano-Calderon, M.W. Colman, K.A. Raskin, F.J. Hornicek, M. Gebhardt, Use of bisphosphonates in orthopedic surgery: Pearls and pitfalls, Orthopedic Clinics of North America, 45(3), 403-416 (2014). Doi: https://doi.org/10.1016/j.ocl.2014.03.006

11. S.L. Ruggiero, T.B. Dodson, T. Aghaloo, E.R. Carlson, B.B. Ward, D. Kademani, American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update, Journal of Oral and Maxillofacial Surgery, 80(5), 920-943 (2022). Doi: https://doi.org/10.1016/j.joms.2022.02.008

12. K.N. Tu, J.D. Lie, C.K.V. Wan, M. Cameron, A.G. Austel, J.K. Nguyen, K. Van, D. Hyun, Osteoporosis: A review of treatment options, P & T, 43(2), 92-104 (2018). URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768298/pdf/ptj4302092.pdf

13. S.R. Malwal, B. O’Dowd, X. Feng, P. Turhanen, C. Shin, J. Yao, B.K. Kim, N. Baig, T. Zhou, S. Bansal, et al., Bisphosphonate-generated ATP-analogs inhibit cell signaling pathways, Journal of the American Chemical Society, 140(24), 7568-7578 (2018). Doi: https://doi.org/10.1021/jacs.8b02363

14. S. Cremers, S. Papapoulos, Pharmacology of bisphosphonates, Bone, 49(1), 42-49 (2011). Doi: https://doi.org/10.1016/j.bone.2011.01.014

15. K. Ganesan, A. Goyal, D. Roane, Bisphosphonate, StatPearls [Internet], National Library of Medicine, 2022. URL: https://pubmed.ncbi.nlm.nih.gov/29262103/

16. S. Kalra, V. Jain, Dental complications and management of patients on bisphosphonate therapy: A review article, Journal of Oral Biology and Craniofacial Research, 3(1), 25-30 (2013). Doi: https://doi.org/10.1016/j.jobcr.2012.11.001

17. L. Arboleya, M. Alperi, S. Alonso, Efectos adversos de los bisfosfonatos, Reumatología Clínica, 7(3), 189-197 (2011). Doi: https://doi.org/10.1016/j.reuma.2010.10.005

18. A. Izzotti, M. Menini, A. Pulliero, G. Dini, C. Cartiglia, P. Pera, D. Baldi, Biphosphonates-associated osteonecrosis of the jaw: The role of gene-environment interaction, Journal of Preventive Medicine and Hygiene, 54(3), 138-145 (2013). URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718369/pdf/1121-2233-54-138.pdf

19. H. Bansal, Medication-related osteonecrosis of the jaw: An update, National Journal of Maxillofacial Surgery, 13(1), 5-10 (2022). URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326203/pdf/NJMS-13-5.pdf

20. D. Rosella, P. Papi, R. Giardino, E. Cicalini, L. Piccoli, G. Pompa, Medicationrelated osteonecrosis of the jaw: Clinical and practical guidelines, Journal of International Society of Preventive and Community Dentistry, 6(2), 97-104 (2016). Doi: https://doi.org/10.4103/2231-0762.178742

21. S. Kuehn, R. Scariot, M. Elsalanty, Medication-related osteonecrosis: Why the jawbone? Dentistry Journal, 11(5), 109 (2023). Doi: https://doi.org/10.3390/dj11050109

22. L.D. Carbonare, M. Mottes, M.T. Valenti, Medication-related osteonecrosis of the jaw (MRONJ): Are antiresorptive drugs the main culprits or only accomplices? The triggering role of vitamin D deficiency, Nutrients, 13(2), 561 (2021). Doi: https://doi.org/10.3390/nu13020561

23. T. Suzuki, R. Sekiya, Y. Hamada, M. Takahashi, K. Karakida, H. Sakamoto, Fatal bleeding in conjunction with mandibular medication-related osteonecrosis of the jaw (MRONJ), The Bulletin of Tokyo Dental College, 59(1), 27-34 (2018). Doi: https://doi.org/10.2209/tdcpublication.2016-0052

24. L.-Y. Wei, S.-H. Kok, Y.-C. Lee, W.-Y. Chiu, J.-J. Wang, S.-J. Cheng, H.-H. Chang, J.-J. Lee, Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients, Oral Diseases, 28(1), 182-192 (2022). Doi: https://doi.org/10.1111/odi.13737

25. C. Scully, C. Madrid, J. Bagan, Dental endosseous implants in patients on bisphosphonate therapy, Implant Dentistry, 15(3), 212-218 (2006). Doi: https://doi.org/10.1097/01.id.0000236120.22719.02

26. G. Campisi, R. Mauceri, F. Bertoldo, V. Fusco, A. Bedogni, A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: A hypothesis, Head & Face Medicine, 17, 25 (2021). Doi: https://doi.org/10.1186/s13005-021-00280-4

27. A. Yuan, A. Munz, S. Reinert, S. Hoefert, Histologic analysis of medicationrelated osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 129(2), 133-140 (2020). Doi: https://doi.org/10.1016/j.oooo.2019.08.018

28. T.B. Dodson, The frequency of medication-related osteonecrosis of the jaw and its associated risk factors, Oral and Maxillofacial Surgery Clinics of North America, 27(4), 509-516 (2015). Doi: https://doi.org/10.1016/j.coms.2015.06.003

29. L. dos Santos-Ferreira, L.G. Abreu, C.B. Calderipe, M.D. Martins, L.F. Schuch, A.C.U. Vasconcelos, Is teriparatide therapy efective for medication‐related osteonecrosis of the jaw? A systematic review and meta‐analysis, Osteoporosis International, 32(12), 2449-2459 (2021). Doi: https://doi.org/10.1007/s00198-021-06078-z

30. A. Muthukrishnan, L. Bijai, G. Ramalingam, Medication-related osteonecrosis of the jaw: a dentist’s nightmare, BMJ Case Reports, 2016, bcr2016214626 (2016). Doi: https://doi.org/10.1136/bcr-2016-214626

31. J.-H. Park, A.M. Alfafara, Y.L. Park, J.-H. Bae, S.-J. Kim, Medication-related osteonecrosis of the maxilla: Prognosis of oral surgery combined with endoscopic sinus surgery, Oral Diseases, 27(4), 962-969 (2021). Doi: https://doi.org/10.1111/odi.13615

32. E. Yamachika, M. Matsubara, A. Ikeda, T. Matsumura, N. Moritani, S. Iida, Treatment of Osteonecrosis of the Jaw, Journal of Craniofacial Surgery, 26(7), e575-e577 (2015). Doi: https://doi.org/10.1097/SCS.0000000000002127

33. F.-J. Rodriguez-Lozano, R.-E. Oñate-Sánchez, Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents, Medicina Oral, Patología Oral, Cirugía Bucal, 21(5), e595-e600 (2016). URL: http://www.medicinaoral.com/medoralfree01/aop/20980.pdf

34. P. Procacci, M. Albanese, L. Trevisiol, V. Favero, D. Bertossi, F. Lonardi, A. D’Agostino, E. Manfrin, P.F. Nocini, Medication related osteonecrosis of the posterior maxilla: Surgical treatment using a combined transnasal endoscopic and intraoral approach, our experience with seven consecutive patients, Clinical Otolaryngology, 43(2), 685-691 (2018). Doi: https://doi.org/10.1111/coa.12999

35. H.C. Schwartz, American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 Update and CTX, Journal of Oral and Maxillofacial Surgery, 73(3), 377 (2015). Doi: https://doi.org/10.1016/j.joms.2014.10.035

36. O. Di Fede, V. Panzarella, R. Mauceri, V. Fusco, A. Bedogni, L. Lo Muzio, SIPMO ONJ Board, G. Campisi, The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention, Biomed Research International, 2018, 2684924 (2018). Doi: https://doi.org/10.1155/2018/2684924

37. M. Kaczoruk-Wieremczuk, P. Adamska, Ł.J. Adamski, P. Wychowanski, B.A. Jereczek-Fossa, A. Starzynska, Oral surgery procedures in a patient with Hajdu-Cheney syndrome treated with Denosumab-A rare case report, International Journal of Environmental Research and Public Health, 18(17), 9099 (2021). Doi: https://doi.org/10.3390/ijerph18179099

38. G. Ficarra, F. Beninati, Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects, Head and Neck Pathology, 1(2), 132-140 (2007). Doi: https://doi.org/10.1007/s12105-007-0033-2

39. H. Al Farii, S. Zhou, A. Albers, Management of osteomyelitis in sickle cell disease: Review article, JAAOS: Global Research and Reviews, 4(9), e20.00002-e20.00010 (2020). Doi: https://doi.org/10.5435/JAAOSGlobal-D-20-00002

40. A.A. Owosho, C.L. Estilo, J.M. Huryn, S.K. Yom, Pentoxifylline and tocoferol in the management of cancer patients with medication-related osteonecrosis of the jaw: An observational retrospective study of initial case series, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 122(4), 455-459 (2016). Doi: https://doi.org/10.1016/j.oooo.2016.06.019

41. H. Squires, E. Simpson, Y. Meng, S. Harnan, J.W. Stevens, R. Wong, S. Thomas, J. Michaels, G. Stansby, A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease, Health Technology Assessment, 15(40), 1-228 (2011). Doi: https://doi.org/10.3310/hta15400

42. P. Lorz-Ulloa, R. Varela-Guillén, La prueba CTX como evaluador de riesgo en el diagnóstico y tratamiento de osteonecrosis de los maxilares inducida por el uso de bifosfonatos, ODOVTOS-International Journal of Dental Sciences, 17(1), 41-51 (2015). Doi: https://doi.org/10.15517/ijds.v0i0.22044

43. M.C. Cortés-Motta, R. Fernández-Grisales, Osteonecrosis de los maxilares: Fisiopatología, diagnóstico y tratamiento, Revista CES: Odontología, 29(2), 65-77 (2016). URL: http://www.scielo.org.co/pdf/ceso/v29n2/v29n2a08.pdf

44. A. Baba, T.K. Goto, H. Ojiri, M. Takagiwa, C. Hiraga, M. Okamura, S. Hasegawa, Y. Okuyama, N. Ogino, H. Yamauchi, et al., CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaws, Dentomaxillofacial Radiology, 47(4), 20170323 (2018). Doi: https://doi.org/10.1259/dmfr.20170323

45. W.B. Williams, F. O’Ryan, Management of medication-related osteonecrosis of the jaw, Oral and Maxillofacial Surgery Clinics of North America, 27(4), 517-525 (2015). Doi: https://doi.org/10.1016/j.coms.2015.06.007

46. N. Ohga, Y. Yamazaki, K. Tsuboi, Y. Kitagawa, Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: A case report and hypothesis, Quintessence International (Berlin), 46(7), 621-626 (2015). Doi: https://doi.org/10.3290/j.qi.a33528

47. N. Ohga, J. Sato, T. Asaka, M. Morimoto, Y. Yamazaki, Y. Kitagawa, Successful conservative treatment of jaw osteonecrosis caused by denosumab in patients with multiple bone metastasis, Journal of Oral Science, 60(1), 159-162 (2018). Doi: https://doi.org/10.2334/josnusd.17-0027

48. B. Svejda, C. Muschitz, R. Gruber, C. Brandtner, C. Svejda, R.W. Gasser, G. Santler, H.P. Dimai, Positionspapier zur medikamentenassoziierten Osteonekrose des Kiefers (MRONJ), Wiener Medizinische Wochenschrift, 166, 68-74 (2016). doi: https://doi.org/10.1007/s10354-016-0437-2

49. F. Hallmer, O. Bjarnadottir, B. Gotrick, P. Malmstrom, G. Andersson, Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: A population-based study, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 130(3), 252-257 (2020). Doi: https://doi.org/10.1016/j.oooo.2020.04.808

50. H. Ikesue, K. Doi, M. Morimoto, M. Hirabatake, N. Muroi, S. Yamamoto, T. Takenobu, T. Hashida, Switching from zoledronic acid to denosumab increases the risk for developing medication‐related osteonecrosis of the jaw in patients with bone metastases, Cancer Chemotherapy and Pharmacology, 87, 871-877 (2021). Doi: https://doi.org/10.1007/s00280-021-04262-w

51. S. Soutome, S. Hayashida, M. Funahara, Y. Sakamoto, Y. Kojima, S. Yanamoto, M. Umeda, Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor? PLoS One, 13(7), e0201343 (2018). Doi: https://doi.org/10.1371/journal.pone.0201343

52. J. Bagan, A. Peydró, J. Calvo, M. Leopoldo, Y. Jiménez, L. Bagan, Medicationrelated osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis, Oral Diseases, 22(4), 324-329 (2016). Doi: https://doi.org/10.1111/odi.12447

53. M. Badr, E. Kyriakidou, A. Atkins, S. Harrison, Aggressive denosumab-related jaw necrosis – A case series, British Dental Journal, 223(1), 13-16 (2017). Doi: https://doi.org/10.1038/sj.bdj.2017.573

54. N. Ueda, C. Nakashima, K. Aoki, H. Shimotsuji, K. Nakaue, H. Yoshioka, S. Kurokawa, Y. Imai, T. Kirita, Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents? Clinical Oral Investigations, 25(5), 3087- 3093 (2021). Doi: https://doi.org/10.1007/s00784-020-03632-7

55. M.A. Altay, A. Radu, S.E. Pack, N. Yıldırımyan, A. Flores-Hidalgo, D.A. Baur, F.A. Quereshy, Medication-related osteonecrosis of the jaw: An institution’s experience, CRANIO®: The Journal of Craniomandibular & Sleep Practice, 38(5), 333-341 (2020). Doi: https://doi.org/10.1080/08869634.2018.1528711

56. N. Adachi, Y. Ayukawa, N. Yasunami, A. Furuhashi, M. Imai, K. Sanda, I. Atsuta, K. Koyano, Preventive effect of fuvastatin on the development of medicationrelated osteonecrosis of the jaw, Scientific Reports, 10(1), 5620 (2020). Doi: https://doi.org/10.1038/s41598-020-61724-6

57. R. Correia-Cavalcante, G. Tomasetti, Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: A systematic literature review, Journal of Cranio-Maxillofacial Surgery, 48(11), 1080-1086 (2020). Doi: https://doi.org/10.1016/j.jcms.2020.09.008

58. O. Ristow, C. Gerngroß, M. Schwaiger, B. Hohlweg-Majert, V. Kehl, H. Jansen, L. Hahnefeld, S. Koerdt, S. Otto, C. Pautke, Effect of antiresorptive drugs on bony turnover in the jaw: Denosumab compared with bisphosphonates, British Journal of Oral and Maxillofacial Surgery, 52, 308-313 (2014). Doi: https://doi.org/10.1016/j.bjoms.2014.01.021

59. Y. Myoken, Y. Fujita, K. Kawamoto, S. Toratani, Osteonecrosis of the jaw in a metastatic lung cancer patient with bone metastases undergoing pembrolizumab + denosumab combination therapy: Case report and literature review, Oral Oncology, 111, 104874 (2020). Doi: https://doi.org/10.1016/j.oraloncology.2020.104874

60. T.M. You, K.-H. Lee, S.-H. Lee, W. Park, Denosumab-related osteonecrosis of the jaw: A case report and management based on pharmacokinetics, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 120(5), 548-553 (2015). Doi: https://doi.org/10.1016/j.oooo.2015.07.017

61. O. Wasserzug, I. Kaffe, T.S. Lazarovici, T. Weissman, R. Yahalom, D.M. Fliss, N. Yarom, Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: Radiologic aspects, American Journal of Rhinology & Allergy, 31(1), 36-39 (2017). Doi: https://doi.org/10.2500/ajra.2017.31.4395

62. P.J. Voss, P. Poxleitner, R. Schmelzeisen, A. Stricker, W. Semper-Hogg, Update MRONJ and perspectives of its treatment, Journal of Stomatology, Oral and Maxillofacial Surgery, 118(4), 232-235 (2017). Doi: https://doi.org/10.1016/j.jormas.2017.06.012

63. G. Maluf, M. Correia de Pinho, S.R.d.B. da Cunha, P.S. da Silva-Santos, E. Rodrigues-Fregnani, Surgery combined with LPRF in denosumab osteonecrosis of the jaw: Case report, Brazilian Dental Journal, 27(3), 353-358 (2016). Doi: https://doi.org/10.1590/0103-6440201600662

64. R. Schoenhof, A. Munz, A. Yuan, A. ElAyouti, H. Boesmueller, G. Blumenstock, S. Reinert, S. Hoefert, Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis, Journal of Cranio-Maxillofacial Surgery, 49(6), 508-517 (2021). Doi: https://doi.org/10.1016/j.jcms.2021.02.018

65. S. Otto, C. Pautke, T.V. den Wyngaert, D. Niepel, M. Schiødt, Medicationrelated osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases, Cancer Treatment Reviews, 69, 177-187 (2018). Doi: https://doi.org/10.1016/j.ctrv.2018.06.007

66. G. Dupic, D. Collangettes, A.-F. Dillies, L. Calvet, O. Tournilhac, J.-O. Bay, H. Mahammedi, Ostéonécrose des maxillaires liée aux bisphosphonates et denosumab: épidémiologie, diagnostic et traitement, Bulletin du Cancer, 102(12), 1010-1019 (2015). Doi: https://doi.org/10.1016/j.bulcan.2015.10.009

67. S. Otto, C. Pautke, T.V. den Wyngaert, D. Niepel, M. Schiødt, Medicationrelated osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases, Cancer Treatment Reviews, 69, 177- 187 (2018). Doi: https://doi.org/10.1016/j.ctrv.2018.06.007

68. A.L. Soares, S. Simon, L.H. Gebrim, A.C.P. Nazário, M. Lazaretti-Castro, Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study, Supportive Care in Cancer, 28(5), 2265-2271 (2020). Doi: https://doi.org/10.1007/s00520-019-05044-0

69. T. Dennis, M. Gahan, The prosthodontic management of medication-related osteonecrosis of the jaw: A case report, British Dental Journal, 230(1), 23-26 (2021). Doi: https://doi.org/10.1038/s41415-020-2500-z

70. K. Okuyama, S. Hayashida, S. Rokutanda, A. Kawakita, S. Soutome, S. Sawada, S. Yanamoto, Y. Kojima, M. Umeda, Surgical strategy for medication-related osteonecrosis of the jaw (MRONJ) on maxilla: A multicenter retrospective study, Journal of Dental Sciences, 16(3), 885-890 (2021). Doi: https://doi.org/10.1016/j.jds.2020.12.007

71. M.-H. Kang, D.-K. Lee, C.-W. Kim, I.-S. Song, S.-H. Jun, Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw, Journal of the Korean Association of Oral and Maxillofacial Surgeons, 44(5), 225-231 (2018). Doi: https://doi.org/10.5125/jkaoms.2018.44.5.225

72. H. Miyashita, K. Kameyama, M. Morita, T. Nakagawa, T. Nakahara, Threedimensional radiologic–pathologic correlation of medication-related osteonecrosis of the jaw using 3D bone SPECT/CT imaging, Dentomaxillofacial Radiology, 48(8), 20190208 (2019). Doi: https://doi.org/10.1259/dmfr.20190208

73. G.D.A. Ayala, V.J.E. Miranda, C.Y.J. Torres, C.A. Uribe, Actualización de medicamentos asociados a necrosis avascular de los maxilares. Perspectiva y revisión de literatura, Revista ADM, 77(4), 197-202 (2020). Doi: https://doi.org/10.35366/95113

74. M.S. Puche, C.C. Astié, M. Fontana, E. Jorquera, G. Alonso, G. Caputo, F. Sansone, M. Porcel, C. Aguado, Agentes antirresortivos y antiangiogénicos y su relación con la osteonecrosis de los maxilares asociada a medicamentos. Revisión narrativa, Revista de la Asociación Odontológica Argentina, 107, 72-78 (2019). URL: https://docs.bvsalud.org/biblioref/2019/09/1016110/puche-agentesantirresortivos-y-antiangiogenicos-y-su-relacion.pdf

75. R. Mauceri, V. Panzarella, I. Morreale, G. Campisi. Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib, International Journal of Oral & Maxillofacial Surgery, 48(12), 1530-1532 (2019). Doi: https://doi.org/10.1016/j.ijom.2019.07.010

76. C.Y.S. Lee, J.B. Suzuki, Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): Report of 4 Cases, Implant Dentistry, 24(2), 227-231 (2015). URL: https://journals.lww.com/implantdent/Fulltext/2015/04000/Medication_Related_Osteonecrosis_of_the_Jaws_From.18.aspx

77. I. Ogura, Y. Sasaki, M. Sue, T. Oda, A. Kameta, K. Hayama, Tc-99m hydroxymethylene diphosphonate scintigraphy, computed tomography, and magnetic resonance imaging of osteonecrosis in the mandible: Osteoradionecrosis versus medication-related osteonecrosis of the jaw, Imaging Science in Dentistry, 49(1), 53-58 (2019). Doi: https://doi.org/10.5624/isd.2019.49.1.53

78. O. Ristow, C. Gerngroß, M. Schwaiger, B. Hohlweg-Majert, M. Ristow, S. Koerdt, R. Schuster, S. Otto, C. Pautke, Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw? Journal of Cancer Research and Clinical Oncology, 140, 487-493 (2014). Doi: https://doi.org/10.1007/s00432-014-1588-4

79. O. Nicolatou-Galitis, M. Schiødt, R.A. Mendes, C. Ripamonti, S. Hope, L. Drudge-Coates, D. Niepel, T.V. den Wyngaert, Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 127(2), 117-135 (2019). Doi: https://doi.org/10.1016/j.oooo.2018.09.008

80. A. Jose, A. Rawat, S.A. Nagori, S. Arya, D. Shukla, Outcomes of sequestrectomy and buccal fat pad reconstruction in the management of medication‐related osteonecrosis of the jaws, Oral and Maxillofacial Surgery, 26(1), 147-153 (2022). Doi: https://doi.org/10.1007/s10006-021-00973-9

81. S. Aljohani, R. Gaudin, J. Weiser, M. Tröltzsch, M. Ehrenfeld, G. Kaeppler, R. Smeets, S. Otto, Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series, Journal of Cranio-Maxillofacial Surgery, 46(9), 1515-1525 (2018). Doi: https://doi.org/10.1016/j.jcms.2018.05.046

82. R.C. de Souza-Póvoa, D.A. Alves-Marlierè, H. Martins da Silveira, F. Ramoa-Pires, Denosumab-related osteonecrosis of the jaws: successful management with a conservative surgical approach, Special Care in Dentistry, 36(4), 231-236 (2016). Doi: https://doi.org/10.1111/scd.12168

83. Y. Thiel, C. Ghayor, D. Lindhorst, H. Essig, F. Weber, M. Rücker, P. Schumann, Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw, Pathology - Research and Practice, 216(12), 153245 (2020). Doi: https://doi.org/10.1016/j.prp.2020.153245

84. S. Kuroshima, M. Sasaki, H. Murata, T. Sawase, Medication‐related osteonecrosis of the jaw‐like lesions in rodents: A comprehensive systematic review and metaanalysis, Gerodontology, 36(4), 313-324 (2019). Doi: https://doi.org/10.1111/ger.12416

85. G. Favia, A. Tempesta, L. Limongelli, A. Crincoli, E. Maiorano, Medicationrelated osteonecrosis of the jaw: Surgical or non-surgical treatment? Oral Diseases, 24(1-2), 238-242 (2018). Doi: https://doi.org/10.1111/odi.12764

86. K. Kiho, S. Sumitomo, M. Tanaka, T. Hasegawa, C. Sakai, Y. Takitani, T. Yoshida, S. Kawano, Pulpal disease arising from medication-related osteonecrosis of the jaw: A case report, Journal of Endodontics, 46(8), 1149-1154 (2020). doi: https://doi.org/10.1016/j.joen.2020.04.010

87. N. Ueda, K. Aoki, H. Shimotsuji, C. Nakashima, M. Kawakami, Y. Imai, T. Kirita, Oral risk factors associated with medication‐related osteonecrosis of the jaw in patients with cancer, Journal of Bone and Mineral Metabolism, 39(4), 623-630 (2021). Doi: https://doi.org/10.1007/s00774-020-01195-x

88. M. Kawahara, S. Kuroshima, T. Sawase, Clinical considerations for medication related osteonecrosis of the jaw: a comprehensive literature review, International Journal of Implant Dentistry, 7(1), 47 (2021). Doi: https://doi.org/10.1186/s40729-021-00323-0

89. O. Ristow, C. Gerngroß, M. Schwaiger, B. Hohlweg-Majert, V. Kehl, H. Jansen, L. Hahnefeld, S. Otto, C. Pautke, Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis? Journal of Oral Maxillofacial Surgery, 72(5), 903-910 (2014). Doi: https://doi.org/10.1016/j.joms.2013.11.005

90. T. Hasegawa, A. Kawakita, N. Ueda, R. Funahara, A. Tachibana, M. Kobayashi, E. Kondou, D. Takeda, Y. Kojima, S. Sato, et al., A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporosis International, 28(8), 2465-2473 (2017). Doi: https://doi.org/10.1007/s00198-017-4063-7

91. H. Ikesue, M. Mouri, H. Tomita, M. Hirabatake, M. Ikemura, N. Muroi, S. Yamamoto, T. Takenobu, K. Tomii, M. Kawakita, et al., Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases, Supportive Care in Cancer, 29, 4763-4772 (2021). Doi: https://doi.org/10.1007/s00520-021-06018-x

92. A. Wutzl, G. Eisenmenger, M. Hoffmann, C. Czerny, D. Moser, P. Pietschmann, R. Ewers, A. Baumann, Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients, Wiener Klinische Wochenschrift, 118(15-16), 473-478 (2016). Doi: https://doi.org/10.1007/s00508-006-0644-8

93. M. Kajizono, H. Sada, Y. Sugiura, Y. Soga, Y. Kitamura, J. Matsuoka, T. Sendo, Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: A retrospective cohort study, Biological and Pharmaceutical Bulletin, 38(12), 1850-1855 (2015). Doi: https://doi.org/10.1248/bpb.b15-00385

94. S. Aljohani, R. Gaudin, J. Weiser, M. Tröltzsch, M. Ehrenfeld, G. Kaeppler, R. Smeets, S. Otto, Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series, Journal of Cranio-Maxillofacial Surgery, 46(9), 1515-1525 (2018). Doi: https://doi.org/10.1016/j.jcms.2018.05.046

95. C.V. Lyttle, H. Paterson, Denosumab: A case of MRONJ with resolution, British Dental Journal, 220, 623-625 (2016). Doi: https://doi.org/10.1038/sj.bdj.2016.443

96. N. Heim, W. Götz, F.-J. Kramer, A. Faron, Antiresorptive drug-related changes of the mandibular bone density in medication-related osteonecrosis of the jaw patients, Dentomaxillofacial Radiology, 48(8), 20190132 (2019). Doi: https://doi.org/10.1259/dmfr.20190132

97. E.R. Carlson, J.D. Basile, The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws, Journal of Oral and Maxillofacial Surgery, 67(5), 85-95 (2009). Doi: https://doi.org/10.1016/j.joms.2009.01.006

98. I. Ogura, Y. Sasaki, M. Sue, T. Oda, A. Kameta, K. Hayama, Tc-99m hydroxymethylene diphosphonate scintigraphy, computed tomography, and magnetic resonance imaging of osteonecrosis in the mandible: Osteoradionecrosis versus medication-related osteonecrosis of the jaw, Imaging Science in Dentistry, 49(1), 53-58 (2019). Doi: https://doi.org/10.5624/isd.2019.49.1.53

99. C. Foncea, K. von Bischhoffshausen, C. Teuber, H. Ramírez, I. Goñi, C. Sánchez, I.N. Retamal, A. Vargas, Osteonecrosis de los maxilares asociada a medicamentos: revisión de la literatura y propuesta para la prevención y manejo, Revista Médica de Chile, 148(7), 983-991 (2020). Doi: https://doi.org/10.4067/S0034-98872020000700983

100. K. Walton, T.R. Grogan, E. Eshaghzadeh, D. Hadaya, D.A. Elashoff, T.L. Aghaloo, S. Tetradis, Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients—quantifying radiographic appearance and relationship to clinical findings, Dentomaxillofacial Radiology, 48(1), 20180128 (2019). Doi: https://doi.org/10.1259/dmfr.20180128

101. C. Klingelhöffer, F. Zeman, J. Meier, T.E. Reichert, T. Ettl, Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws, Journal of Cranio-Maxillofacial Surgery, 44(10), 1694-1699 (2016). Doi: https://doi.org/10.1016/j.jcms.2016.08.001

102. S. Matsuda, H. Yoshida, M. Shimada, H. Yoshimura, Spontaneous regeneration of the mandible following hemimandibulectomy for medication-related osteonecrosis of the jaw, Medicine (Baltimore), 99(33), e21756 (2020). Doi: https://doi.org/10.1097/MD.0000000000021756

103. R. Ogawa, Y. Minami, J. Ono, Y. Kanri, E. Kobayashi, A. Tanaka, Y. Okada, I. Ogura, Medication-related osteonecrosis of the jaw in a patient with multiple myeloma: an unusual case with tumor in the surgical specimen, Oral Radiology, 38(2), 288-291 (2022). Doi: https://doi.org/10.1007/s11282-021-00560-4

104. C. Blus, G. Giannelli, S. Szmukler-Moncler, G. Orru, Treatment of medicationrelated osteonecrosis of the jaws (MRONJ) with ultrasonic piezoelectric bone surgery. A case series of 20 treated sites, Oral and Maxillofacial Surgery, 21(1), 41-48 (2017). Doi: https://doi.org/10.1007/s10006-016-0597-7

Cómo citar

APA

Cuenca-León, K., Riofrio, D., Reinoso-Quezada, S., Solano-Jara, A., Cuenca-León, J. y Pacheco-Quito, E.-M. (2025). Medication-related osteonecrosis of the jaw (MRONJ). Revista Colombiana de Ciencias Químico-Farmacéuticas, 53(3), 831–862. https://doi.org/10.15446/rcciquifa.v53n3.119215

ACM

[1]
Cuenca-León, K., Riofrio, D., Reinoso-Quezada, S., Solano-Jara, A., Cuenca-León, J. y Pacheco-Quito, E.-M. 2025. Medication-related osteonecrosis of the jaw (MRONJ). Revista Colombiana de Ciencias Químico-Farmacéuticas. 53, 3 (mar. 2025), 831–862. DOI:https://doi.org/10.15446/rcciquifa.v53n3.119215.

ACS

(1)
Cuenca-León, K.; Riofrio, D.; Reinoso-Quezada, S.; Solano-Jara, A.; Cuenca-León, J.; Pacheco-Quito, E.-M. Medication-related osteonecrosis of the jaw (MRONJ). Rev. Colomb. Cienc. Quím. Farm. 2025, 53, 831-862.

ABNT

CUENCA-LEÓN, K.; RIOFRIO, D.; REINOSO-QUEZADA, S.; SOLANO-JARA, A.; CUENCA-LEÓN, J.; PACHECO-QUITO, E.-M. Medication-related osteonecrosis of the jaw (MRONJ). Revista Colombiana de Ciencias Químico-Farmacéuticas, [S. l.], v. 53, n. 3, p. 831–862, 2025. DOI: 10.15446/rcciquifa.v53n3.119215. Disponível em: https://revistas.unal.edu.co/index.php/rccquifa/article/view/119215. Acesso em: 29 mar. 2025.

Chicago

Cuenca-León, Katherine, Darlin Riofrio, Santiago Reinoso-Quezada, Anabel Solano-Jara, Jaime Cuenca-León, y Edisson-Mauricio Pacheco-Quito. 2025. «Medication-related osteonecrosis of the jaw (MRONJ)». Revista Colombiana De Ciencias Químico-Farmacéuticas 53 (3):831-62. https://doi.org/10.15446/rcciquifa.v53n3.119215.

Harvard

Cuenca-León, K., Riofrio, D., Reinoso-Quezada, S., Solano-Jara, A., Cuenca-León, J. y Pacheco-Quito, E.-M. (2025) «Medication-related osteonecrosis of the jaw (MRONJ)», Revista Colombiana de Ciencias Químico-Farmacéuticas, 53(3), pp. 831–862. doi: 10.15446/rcciquifa.v53n3.119215.

IEEE

[1]
K. Cuenca-León, D. Riofrio, S. Reinoso-Quezada, A. Solano-Jara, J. Cuenca-León, y E.-M. Pacheco-Quito, «Medication-related osteonecrosis of the jaw (MRONJ)», Rev. Colomb. Cienc. Quím. Farm., vol. 53, n.º 3, pp. 831–862, mar. 2025.

MLA

Cuenca-León, K., D. Riofrio, S. Reinoso-Quezada, A. Solano-Jara, J. Cuenca-León, y E.-M. Pacheco-Quito. «Medication-related osteonecrosis of the jaw (MRONJ)». Revista Colombiana de Ciencias Químico-Farmacéuticas, vol. 53, n.º 3, marzo de 2025, pp. 831-62, doi:10.15446/rcciquifa.v53n3.119215.

Turabian

Cuenca-León, Katherine, Darlin Riofrio, Santiago Reinoso-Quezada, Anabel Solano-Jara, Jaime Cuenca-León, y Edisson-Mauricio Pacheco-Quito. «Medication-related osteonecrosis of the jaw (MRONJ)». Revista Colombiana de Ciencias Químico-Farmacéuticas 53, no. 3 (marzo 17, 2025): 831–862. Accedido marzo 29, 2025. https://revistas.unal.edu.co/index.php/rccquifa/article/view/119215.

Vancouver

1.
Cuenca-León K, Riofrio D, Reinoso-Quezada S, Solano-Jara A, Cuenca-León J, Pacheco-Quito E-M. Medication-related osteonecrosis of the jaw (MRONJ). Rev. Colomb. Cienc. Quím. Farm. [Internet]. 17 de marzo de 2025 [citado 29 de marzo de 2025];53(3):831-62. Disponible en: https://revistas.unal.edu.co/index.php/rccquifa/article/view/119215

Descargar cita

CrossRef Cited-by

CrossRef citations0

Dimensions

PlumX

Plum Print visual indicator of research metrics
No metrics available.
-
see details

Visitas a la página del resumen del artículo

17

Descargas

Licencia

Derechos de autor 2025 Revista Colombiana de Ciencias Químico-Farmacéuticas

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia  autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.

Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13